5-(4-Difluoromethoxy-phenyl)-1 H -pyrazole-3-carboxylic acid, 95+%, 1g

4-(4-Bromophenyl)oxane-4-carbonitrile, 95.0%, 500mg

4-Phenylazobenzyloxycarbonyl-Pro-OH, 95.0%, 1g

Methyl 3-fluoropyridine-2-carboxylate, 95.0%, 10g

4,4',4'',4'''-([2,2'-Bi(1,3-dithiolylidene)]-4,4',5,5'-tetrayl)tetraaniline, 97%, 100mg

7-Amino-1H-indole-3-carbonitrile, 95%, 5g

3-(2-Aminoethoxy)pyridine, 95.0%, 250mg

(E)-3-(2-Methoxypyridin-3-yl)acrylic acid, 98%, 5g

Methyl (4aS,4bS,6aS,7S,9aS,9bS,11aR)-3-fluoro-1,4a,6a-trimethyl-2-oxo-2,4a,4b,5,6,6a,7,8,9,9a,9b,10,11,11a-tetradecahydro-1H-indeno[5,4-f]quinoline-7-carboxylate, 98%, 250mg

5-((1,4-Diazepan-1-yl)sulfonyl)isoquinolin-1(2H)-one, 95.0%, 50mg

GC capillary column ROTI®Cap-1701, 25 m, 0.53 mm, 2.00 µm, 1 Piece(s)

2,4-Dimethyl-5-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)-oxazole, 98%, 100mg

Silicon(IV) acetate 50 g